89bio, Inc
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch 89bio, Inc and buy or sell other stocks, ETFs, and their options commission-free!About ETNB
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG.
CEORohan Palekar, MBA
CEORohan Palekar, MBA
Employees93
Employees93
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded2018
Founded2018
Employees93
Employees93
ETNB Key Statistics
Market cap2.20B
Market cap2.20B
Price-Earnings ratio-4.12
Price-Earnings ratio-4.12
Dividend yield—
Dividend yield—
Average volume7.10M
Average volume7.10M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$15.06
52 Week high$15.06
52 Week low$4.16
52 Week low$4.16
Stock Snapshot
With a market cap of 2.2B, 89bio, Inc(ETNB) trades at $14.84. The stock has a price-to-earnings ratio of -4.12.
On 2025-12-05, 89bio, Inc(ETNB) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for 89bio, Inc(ETNB) stock has reached 0, versus its average volume of 7.1M.
Over the past 52 weeks, 89bio, Inc(ETNB) stock has traded between a high of $15.06 and a low of $4.16.
Over the past 52 weeks, 89bio, Inc(ETNB) stock has traded between a high of $15.06 and a low of $4.16.
People also own
Based on the portfolios of people who own ETNB. This list is generated using Robinhood data, and it’s not a recommendation.